SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after a significant drop following mixed Phase 3 trial results, specifically related to high placebo response impacting statistical significance. The conversation centers on whether the sell-off is an overreaction given the company's cash reserves and ongoing pipeline, with some speculating about a potential buyout and others wary of the mixed data. Community members are actively discussing dip-buying strategies, potential bounce-back scenarios, and comparisons to competitor performance.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Shares of Robinhood are trending as the stock rallies to new all-time highs, fueled by optimism around its S&P 500 inclusion and growth in its prediction markets business; the community is closely watching for continued momentum. Several analysts have recently raised their price targets, with some traders speculating on further upside. The stock has become a favorite among millennial traders as it rides the crypto wave and wealth transfer megatrend.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

AUPH is trending due to a sharp drop in stock price following remarks made by a former FDA official, George Tidmarsh, regarding the drug Voclosporin. The community is expressing concerns about the validity and timing of the statement, with some suspecting market manipulation and questioning the company's leadership response. The drop has also impacted buyout hopes.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

MSOS is trending as cannabis stocks react to a video posted by Trump discussing the medical benefits of CBD for seniors, sparking community discussion around potential rescheduling.  Traders are actively weighing the implications of potential policy changes and the sector's volatile nature, while some highlight positive movement in European cannabis markets. The community speculates on the timing and impact of any official announcements.

American Battery Technology Co. is a technology company, which engages in the development and marketing of lithium-ion batteries. Its projects include recycling plant, United States Advanced Battery Consortium (USABC), and Tonopah flats. The company was founded on October 6, 2011 and is headquartered in Reno, NV.

American Battery Technology Company

American Battery Technology Company is trending as investors anticipate the release of its preliminary feasibility study (PFS), with community members expressing excitement and speculating about potential partnerships and government support. Bullish sentiment is fueled by the company's strategic positioning in lithium extraction and battery recycling, as well as recent revenue gains. Some investors are drawing parallels to other successful stocks in the sector, while cautioning about potential short squeezes and profit-taking.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending following news of a partnership with Google to enhance AI-powered shopping experiences. While some investors are excited about the potential growth, others express frustration with the stock's historical underperformance and question whether the partnership will provide an immediate catalyst. Community members are debating whether this is a turning point or another false start for the fintech giant.

Boqii Holding Ltd. operates as a holding company with interest in operating online pet stores. It provides services through its subsidiaries. The company was founded by Liang Hao, Tang Yingzhi, and Chen Di in December 2007 and is headquartered in Shanghai, China.

Boqii Holding Limited - Ordinary Shares - Class A

Boqii Holding Limited - ADR

Boqii Holding is trending due to speculation around a potential gamma squeeze and significant price movement, leading to community discussions about float size and potential price targets. Some traders are pointing to technical indicators and chart patterns, while others caution about the risks associated with Chinese stocks and potential pump-and-dump schemes. The stock's volatility and history of reverse splits are also prominent points of discussion among investors.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopify is trending following a strong earnings report, with revenue and GMV growth exceeding expectations. The community is discussing the company's resilience in the face of potential headwinds like tariffs, along with its expanding partnerships and AI initiatives. Bullish sentiment is fueled by raised price targets and the anticipation of continued growth, though some caution against overvaluation.

"What's Updog?" is a Community Led token.

UpDog

$UPDOG.X is trending, sparking community engagement around the classic 'What's UpDog?' joke. Built on Solana and listed on Jupiter, the community emphasizes its longevity and strong holder base. The conversation also highlights the accessibility of becoming an $UPDOG millionaire.

Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals (ENTA) is trending due to mixed Phase 2b study results for its RSV treatment, zelicapavir, causing investor debate and a stock sell-off. While the primary endpoint was missed, secondary endpoints were met, fueling discussions about the drug's potential and Phase 3 progression, particularly regarding FDA priorities. Community talking points include potential short squeezes given the high short interest and oversold RSI.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Are Medical Stocks Lagging  Boston Scientific (BSX) This Year?

Here is how Boston Scientific (BSX) and Allarity Therapeutics, Inc. (ALLR) have performed compared to their sector so far this year.

Allarity Therapeutics, Inc. (ALLR) on Tuesday announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its Stenoparib. Following the announcement, shares of the company more than doubled in value by Tuesday afternoon.Stenoparib is an investigational treatment for patients with advanced ovarian cancer. FDA’s Fast Track designation is intended to expedite the development and review of drugs that treat serious conditions and fill an unmet medical need. It allows for more frequent interactions with the FDA throughout the drug development process and potentially provides eligibility for accelerated approval and priority review, upon meeting relevant criteria.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ALLR">ALLR stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘extremely low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:575/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_26_at_12_16_43_PM_png_5d0f99e451.webp" alt="ALLR's Sentiment Meter and Message Volume as of 12:17 p.m. ET on Aug. 26, 2025 | Source: Stocktwits" width="575" height="61"><figcaption>ALLR's Sentiment Meter and Message Volume as of 12:17 p.m. ET on Aug. 26, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed surprise at the rally and opined that the stock might drop to below $1 by the end of the day.<stembedurl>https://stocktwits.com/patb99/message/626594104</stembedurl>Another user stated that larger pharmaceutical companies will now be interested in the drug.<stembedurl>https://stocktwits.com/Creyedr/message/626587898</stembedurl>Allarity CEO Thomas Jensen <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/08/26/3139198/0/en/Allarity-Therapeutics-Granted-FDA-Fast-Track-Designation-for-Stenoparib-for-the-Treatment-of-Advanced-Ovarian-Cancer.html">said</a> the company is pleased with the designation. “We look forward to engaging closely with the FDA as we advance this program,” he added.US-headquartered Allarity started patient enrollment under a new mid-stage clinical trial protocol evaluating Stenoparib in advanced, recurrent, platinum-resistant, or platinum-ineligible ovarian cancer in early June 2025. Several patients have already been dosed in the study. The trial is designed to accelerate clinical development of Stenoparib. Previous mid-stage study data showed durable clinical benefit for Stenoparib.The therapy was originally developed by Eisai Co., but Allarity secured exclusive global rights for the development and commercialization.ALLR stock has gained 74% this year but has lost 59% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/regeneron-stock-rallies-after-therapy-for-autoimmune-disease-meets-late-stage-trial-goals/chsvb4wRdjv">Regeneron Stock Rallies After Therapy For Autoimmune Disease Meets Late-Stage Trial Goals: Retail Thinks Stock Might Hit An All-Time Low Soon</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Did Allarity Therapeutics Stock Double In Value Today?

The company’s Stenoparib, an investigational treatment for patients with advanced ovarian cancer, was granted the Fast Track designation by the FDA.

Equity

ReShape Lifesciences Inc. (1,900% Jump in Message Volume)ReShape Lifesciences saw a surge in retail discussion as traders speculated on the potential approval of its proposed reverse merger with Vyome Therapeutics, first announced in June 2024.&nbsp;The metabolic health solutions company stated in January that it was still working with the SEC on its S-4 filing and would set a shareholder meeting date once the filing is declared effective.Some investor interest also stemmed from reports that Michael Bigger’s fund had taken a significant stake in ReShape. However, sentiment remained mixed after the company raised $6 million through a public offering last month.&nbsp;ReShape’s stock is down nearly 80% year-to-date (YTD).Allarity Therapeutics Inc. (1,700% Jump in Message Volume)Allarity drew attention after announcing a Phase 2 trial evaluating the combination of stenoparib, a PARP inhibitor, with the chemotherapy agent temozolomide for treating recurrent small-cell lung cancer (SCLS). Prior studies had shown about a 40% response rate in SCLC patients, but dose-limiting toxicity remained a challenge.Additionally, Allarity’s Board of Directors authorized a $5 million share repurchase program on Monday, allowing buybacks through February 2026.&nbsp;The stock is down over 9% YTD.Exact Sciences Corporation (1,100% Jump in Message Volume)Exact Sciences, known for its cancer diagnostics, saw increased interest as it participated in the TD Cowen 45th Annual Healthcare Conference and Raymond James &amp; Associates’ 46th Annual Institutional Investors Conference last week.&nbsp;The company reiterated its plans to launch three new cancer screening tests in 2025, including Cologuard Plus (a next-generation colorectal cancer screening test), Oncodetect (a molecular residual disease test) and Cancerguard (a multi-cancer screening test).The company noted rising demand for rescreens, which grew 30% last year and are expected to grow another 30% this year.&nbsp;Exact Sciences’ stock is down over 18% YTD.CVS Health Corporation (700% Jump in Message Volume)CVS Health made headlines last week after announcing that Wellvana had acquired its Medicare Shared Savings Program business in an all-stock deal, giving CVS a strategic minority stake in Wellvana.On Saturday, The Wall Street Journal <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/business/retail/cvs-small-store-openings-b0e196a2">reported</a> that CVS plans to open a dozen new stores focused on full-service pharmacies with minimal retail space, a shift in response to declining retail sales across drugstore chains.&nbsp;The stock has gained 47% YTD.AbbVie Inc. (500% Jump in Message Volume)AbbVie’s stock gained traction after BofA raised its price target to $223 from $200, maintaining a ‘Neutral’ rating. The bullish revision followed AbbVie’s $350 million upfront deal with Gubra to develop GUB014295, a long-acting amylin analog targeting obesity.Under the agreement, Gubra could receive up to $1.88 billion in milestone payments, plus tiered royalties on global net sales.&nbsp;AbbVie shares are up nearly 20% YTD.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

ReShape Lifesciences, Allarity, Exact Sciences, CVS, AbbVie: 5 Health Care Stocks That Led Retail Message Growth Last Week

Speculation over an impending reverse merger, a Phase 2 trial announcement, comments about upcoming cancer screening tests, a  Medicare business deal, and an obesity drug partnership sparked buzz among Stocktwits users for the week ended March 7, 2025.

ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Allarity Therapeutics, Inc. (Allarity or the Company) (NASDAQ: ALLR) for...

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Allarity Therapeutics, Inc. (Allarity or the Company) (NASDAQ: ALLR) and reminds investors of...

ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities...

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Allarity Therapeutics, Inc. Inc. of Class Action Lawsuit and Upcoming Deadlines - ALLR

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Allarity Therapeutics, Inc. Inc. of Class Action Lawsuit and Upcoming Deadlines - ALLR SHAREHOLDER ALERT...

ALLR Deadline: Rosen Law Firm Urges Allarity Therapeutics, Inc. (NASDAQ: ALLR) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Rosen Law Firm, a global investor rights law firm, reminds purchasers and acquirers of securities of Allarity Therapeutics, Inc. (NASDAQ: ALLR) between May 17, 2022 and July 19, 2024, both dates...

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Allarity Therapeutics, Inc. (ALLR)

The Law Offices of Frank R. Cruz reminds investors of the upcoming November 12, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Allarity...

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on...

Allarity Therapeutics, Inc. engages in the development of drugs for personalized treatment of cancer guided by its proprietary Drug Response Predictor (DRP) technology. The company operates in two geographic areas: Denmark and the United States. The company was founded on April 4, 2021 and is headquartered in Boston, MA.

Allarity Therapeutics Inc

Just the one

Three

Four

The Fed just cut rates. How many cuts do you expect in all of 2025? 
 
*Powered by Polymarket

Current Price	$1.55
Prev Close	$1.58
Open	$1.57
Dividend Yield	0.00%
50-Day Moving Average	$1.30
Beta	0.59
Avg. Volume	19.85M
PE Ratio	-0.17

52-Week High	$2.35
52-Week Low	$0.6138
Market Capitalization	$23.1M
EPS (Annual)	-$15.79
Price to Book	1.90
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

ALLR
Allarity Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Latest ALLR News

ALLR Allarity Therapeutics Inc